MoonLake Immunotherapeutics - MLTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 02, 2026 | SCHEDULE 13D/A | — | 11.6% | 27,709,362 | View |
| Feb 17, 2026 | SCHEDULE 13G | Cormorant Asset Management, LP | 6.1% | 4,355,433 | View |
| Feb 17, 2026 | SCHEDULE 13G | Bihua Chen | 6.1% | 4,355,433 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Avoro Capital Advisors LLC | 3.15% | 2,000,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Behzad Aghazadeh | 3.15% | 2,000,000 | View |
| Nov 12, 2025 | SCHEDULE 13G | Deep Track Capital, LP | 6.46% | 4,610,071 | View |
| Nov 12, 2025 | SCHEDULE 13G | Deep Track Biotechnology Master Fund, Ltd. | 6.46% | 4,610,071 | View |
| Nov 12, 2025 | SCHEDULE 13G | David Kroin | 6.46% | 4,610,071 | View |
| Nov 10, 2025 | SCHEDULE 13D/A | — | 14.3% | 10,235,089 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | FMR LLC | 1.1% | 726,931 | View |
| Nov 05, 2025 | SCHEDULE 13G/A | Abigail P. Johnson | 1.1% | 726,931 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.